Peptide-Linked Morpholino Antisense Oligonucleotides for Myotonic Dystrophy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for myotonic dystrophy type 1 (DM1) do not effectively target toxic RNA, and existing treatments are mainly supportive, lacking a systemic delivery strategy to address the disease's pathogenic RNA-mediated toxicity across multiple tissues.
Innovation Solution
Development of cationic peptide-linked morpholino antisense oligonucleotides that are systemically administered, comprising a morpholino sequence complementary to polyCUG repeat sequences in the 3' untranslated region of the dystrophia myotonica protein kinase (DMPK) RNA transcript, facilitated by a cell-penetrating peptide for targeted delivery to multiple tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard antisense oligonucleotides are used to target toxic RNA, then sequence-specific binding is achieved, but systemic delivery and tissue penetration are insufficient
Solution Approach 1:
The patent combines morpholino oligonucleotides with cell-penetrating peptides to create a composite therapeutic agent. The morpholino component provides sequence-specific binding to the poly(CUG) repeat tract, while the cell-penetrating peptide component enables systemic delivery and cellular uptake. This composite structure resolves the contradiction by integrating both binding reliability and delivery efficiency in a single molecule.
2Ease of operation
If supportive therapies are used to manage symptoms, then immediate symptom relief is achieved, but the underlying pathogenic RNA-mediated toxicity is not addressed
Solution Approach 1:
The patent extracts and targets the root cause of the disease by designing an antisense oligonucleotide that specifically binds to the poly(CUG) repeat tract in the DMPK RNA transcript. This extraction approach removes the pathogenic element (toxic RNA) from the system, thereby addressing the underlying disease mechanism rather than merely managing symptoms.
3Reliability
If larger oligonucleotide sequences are used to target extended polyCUG repeats, then binding coverage is improved, but cellular uptake and delivery efficiency decrease
Solution Approach 1:
The patent changes the chemical parameters of the oligonucleotide by using morpholino backbone instead of traditional phosphodiester or phosphorothioate backbones. This parameter change allows the oligonucleotide to maintain stability and binding affinity while improving cellular permeability and reducing size-related delivery barriers, thereby resolving the contradiction between binding coverage and delivery efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cationic peptide-linked morpholino antisense oligonucleotides effectively penetrate muscle cells, neutralize toxic RNA effects, correct splicing defects, release sequestered proteins, and alleviate myotonia, demonstrating systemic efficacy in animal models of DM1.
Implementation Method 1
a cell-penetrating peptide for targeted delivery to multiple tissues
Implementation Method 2
a morpholino sequence complementary to polyCUG repeat sequences in the 3' untranslated region of the dystrophia myotonica protein kinase (DMPK) RNA transcript
Data Source
Figure 1a~1b
Figure 2
Figure 3
AI summary
Provided herein are peptide-linked morpholino (PPMO) antisense oligonucleotides that target the poly CUG repeat tract in the 3' untranslated region of the gene encoding dystrophia myotonica-protein kinase (DMPK) and methods for systemic administration of the same for the treatment of mytonic dystrophy type I (DM1).